Abstract: Improved ingestible event markers are provided. Aspects of the markers may include the presence of a matrix layer that includes a binder and source of an electron acceptor. Alternatively or in addition to the matrix layer, aspects of the markers may include a large surface area electrode having a surface area that exceeds the surface area of the circuitry of the marker. Aspects further include methods of making and using the ingestible event markers.

Abstract: Provided is a novel heterocyclic compound having an aryl hydrocarbon receptor antagonist activity and useful for the promotion of platelet production, the compound being represented by the general formula [I]: wherein ring A, ring B, R1, R2, R3, R4, n, and X are as defined above, or a salt thereof.

Abstract: A system, a wearable device, and a method are provided which can increase the accuracy of physiological metrics while detecting if the patient ingested digital medicine and/or improve performance of the wearable device. The wearable device can comprise machine executable instructions that when executed by the processor, cause the processor to perform various algorithms, such as, for example, at least one of a step count algorithm, a body angle algorithm, a heart rate algorithm, a peak finder algorithm, an adaptive thresholding algorithm, a heart rate variability algorithm, a R-R cleaning Algorithm, a deltaR-R cleaning algorithm, a merge twin interval algorithm, a split tall intervals algorithm, an absorb short intervals algorithm, a bimodal detection algorithm, and a resting algorithm.

Abstract: A target authentication device includes an electrode to detect an electrical signal associated with a user of the device. The electrical signal represents an authentication code for the device. An authentication receiver module is coupled to the electrode. The module receives the electrical signal from the electrode and determines whether the electrical signal matches a predetermined criterion to authenticate the identity of the user based on the electrical signal. An authentication module is also disclosed. The authentication module includes one electrode to couple an electrical signal associated with a user to a user of a target authentication device, the electrical signal represents an authentication code for the device. An authentication transmission module is coupled to the electrode. The authentication transmission module transmits the electrical signal from the electrode. A method of authenticating the identity of a user of a target authentication device also is disclosed.

Abstract: The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.

Abstract: An object of the present invention is to provide a freeze-dried aripiprazole powder formulation that exhibits good dispersibility and is easily dispersed into a homogenous suspension when reconstituted with water. The present invention provides a freeze-dried aripiprazole formulation obtained by a process comprising the steps of spraying for freezing an aripiprazole suspension containing (I) aripiprazole, (II) a vehicle for the aripiprazole, and (III) water for injection, and drying.

Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.

Abstract: Highly-swellable polymeric films are provided. Aspects also include ingestible compositions that include the highly-swellable polymeric film and an ingestible component. Aspects further include methods of making and using the compositions.

Abstract: This invention relates to the compound (2R)-2-(6-{5-chloro-2-[(oxan-4-yl)amino]pyrimidin-4-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)-N-[(1S)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]propanamide, and in particular to novel physical forms of the compound, a process for preparing the compound and synthetic intermediates for use in the process, and novel formulations containing the compound, as well as therapeutic uses of the compound.

Abstract: An improved process for preparing 2-chloro-4-nitroimidazole derivatives which are useful intermediates in the preparation of an anti-tuberculosis drug is provided. The process may comprise the step of chlorinating nitroimidazoles with a chlorinating agent and an activating agent to give 2-chloro-4-nitroimidazole derivatives.

Abstract: An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 s?1 and having a viscosity of 0.2 pascal-seconds or less in at least one point in the shear rate range of 900 to 1,000 s?1, as measured.

Abstract: The present invention relates to a method of production of 4-boronophenylalanine (BPA) from 4-iodophenylalanine, in which all the functional groups of the amino acid are protected by benzyl protection method, and which uses isopropyl magnesium halogenide stabilized by a complexation base, and subsequent condensation of the resulting Grignard reagent with a boric acid ester. The final reaction step, catalytic hydrogenolysis or transfer hydrogenolysis of protecting groups on the amino acid, occurs after hydrolysis of the boronate ester groups.

Abstract: A method may comprise receiving and sampling a signal. The signal may encode a data packet. A slice may be generated and stored comprising a pair of values for each of a selected number of samples of the signal representing a correlation of the signal to reference functions in the receiver. The presence of the data packet may then be detected and the detected packet decoded from the stored slices. The generating and storing slices may be carried out as the received signal is sampled. The sampled values of the signal may be discarded as the slices are generated and stored. The slice representation of the signal can be manipulated to generate filters with flexible bandwidth and center frequency.

Abstract: Provided is a composition comprising delamanid particles for which the formation of secondary particles is suppressed. Specifically, provided is a composition comprising (A) delamanid particles and (B) a surface stabilizer.

Abstract: The present application provides a method for improvement in physical activity efficiency, a method for reducing fatigue, and a method for improving dynamic/kinetic visual acuity, comprising administering a composition comprising a kaempferol analog to a subject in need thereof.

Abstract: An ingestible compositions includes a first polymer layer, an adhesive layer associated with the first polymer layer, where the adhesive layer includes an adhesive material and is configured to releasably adhere to the first polymer layer, an alginate layer adhered to the adhesive layer, and a second polymer layer associated with the alginate layer and configured to releasably adhere to the alginate layer. Aspects further include methods of making and using the compositions.

Abstract: The present invention further provides a composition for inhibiting purine body absorption, a composition for inhibiting purine nucleotide metabolism, a composition for inhibiting phosphatase, a composition for inhibiting uric acid level elevation, a composition for improving blood pressure, a composition for improving blood glucose level, a composition for improving liver function, a composition for controlling serum iron level, or a composition for promoting calcium absorption, comprising an inositol phosphate or a salt thereof. The present invention further provides a composition comprising an inositol phosphate or a salt thereof, wherein the taste thereof is improved by adding thereto a predetermined amount of calcium lactate.

Abstract: The present invention provides an agent for treating malignant tumor, comprising a compound of formula (1): wherein R1 to R4 are hydrogen atom, halogen, or etc., Y is optionally-substituted alkylene group or etc.

Abstract: The present invention relates to methods and intermediates for synthesizing 2?-deoxy-2?,2?-difluorotetrahydrouridine compounds.

Abstract: A composition for external use is provided, comprising a phosphate ester of uridine or a physiologically acceptable salt thereof as an active ingredient for moisturizing, anti-wrinkling, anti-sagging, wound healing, prevention of hair loss, hair growth, or prevention/treatment of atopic dermatitis.